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Belinda R. Avalos,1 Aleksandr Lazaryan,2 Edward A. Copelan2A large majority of allogeneic hematopoietic stem cell donations are achieved using granulocyte-colony
stimulating factor (G-CSF). G-CSF use has been associated with later development of myelodysplastic syn-
dromes/acute myelogenous leukemia (MDS/AML) in several clinical circumstances. Although clinical data to
date have failed to identify any increased incidence of MDS/AML in G-CSF mobilized donors, the quality of
these data are insufficient to exclude a long-term risk. Physicians should explain the potential risk to donors,
and where appropriate, offer donors the option of marrow donation.
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Granulocyte-colony stimulating factor (G-CSF) is
used in patients with congenital or acquired neutrope-
nia, following chemotherapy for treatment of malig-
nancies, and after both autologous and allogeneic
hematopoietic cell transplantation. It is also routinely
used in healthy donors to mobilize hematopoietic
stem cells into the peripheral blood for collection
and allogeneic transplantation. Although G-CSF is ef-
fective in each of these settings, the development of
myelodysplasia and acute myeloid leukemia (AML)
in some groups of patients who have received G-CSF
has raised concerns about its routine use, particularly
in hematopoietic stem cell donors. In order to analyze
this potential risk, we review here the biology of
G-CSF and its receptor, the mechanisms by which
G-CSFmight contribute to malignant transformation,
the evidence supporting its association with the devel-
opment of hematologic malignancy, and the relevance
of that evidence to hematopoietic stem cell donors.BIOLOGYOF G-CSF AND ITS RECEPTOR
G-CSF, themajor regulator of granulopoiesis, pro-
motes the survival, proliferation, and maturation ofTheOhio State University, Columbus, Ohio; and 2Cleve-
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lineage [1]. The growth of neutrophilic granulocytes
in vitro is dependent on G-CSF and is enhanced by
increasing G-CSF concentrations [2-5]. The G-CSF
receptor (G-CSFR) is a transmembrane protein
expressed on the surface of cells of the neutrophil
lineage. It mediates the biological activities of G-CSF
[4]. The extracellular portion of the receptor binds its
ligand and the cytoplasmic tail transduces intracellular
signals [4,6,7]. Specific regions of the cytoplasmic
domain mediate distinct activities: The membrane-
proximal domain activates proliferative signals,
whereas the distal region induces differentiation sig-
nals. Studies of mice with knock-out or knock-in
G-CSFRmutations demonstrate that the receptor gen-
erates unique signals that maintain circulating PMN
levels during basal and stress granulopoiesis [8-12].
Several G-CSFR isoforms arising from alternative
splicing and differing in their transmembrane or
cytoplasmic sequences have been isolated. The type
IV isoform, in which the 87 carboxy-terminal amino
acids of the full-length Type I G-CSFR are replaced
with a unique 34 amino acid sequence, is defective in
differentiation signaling [13-17]. Increased expression
of this isoform relative to the wild-type I G-CSFR
has been detected in the myeloblasts of some patients
with AML [18].CLINICAL USE
Recombinant human G-CSF (Flgrastim, Neupo-
gen, Amgen Inc.) was the first CSF to receive FDA ap-
proval in the United States. It was initially approved
for the prevention of febrile neutropenia in patients
receiving myelosuppressive chemotherapy after a
placebo-controlled trial demonstrated that G-CSF1739
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duration of neutropenia, hospitalization, and intrave-
nous antibiotic use in this setting [19]. The labeled
indications for G-CSF have subsequently been ex-
panded and include the mobilization of progenitor cells
into the peripheral blood for collection and transplanta-
tion. An expert panel convened by The American Soci-
ety of Clinical Oncology (ASCO) developed practice
guidelines for the use of CSFs initially published in
1994 [20] and updated in 1996 [21], 2000 [22], and
2006 [23]. Appropriate use of G-CSF has been associ-
ated with later development of myelodysplastic syn-
dromes (MDS)/AML in several clinical settings.MDS/AML AFTER G-CSF
Severe Congenital Neutropenia (SCN)
SCN is an inborn disorder of granulopoiesis
frequently associated with mutations in the gene
encoding neutrophil elastase. SCN has a marked
propensity for transformation to MDS/AML with a
cumulative rate that exceeds 20%. Acquired point
mutations in the CSF3R gene (which codes for the
G-CSFR) resulting in truncation of the carboxy-
terminal maturation-inducing region occur in patients
with AMLwith preceding SCN [24]. Expression of the
mutant receptor in myeloid cell lines results in defec-
tive ligand internalization and enhanced proliferative
and survival signals in response to G-CSF [25,26].
Transgenic mice carrying truncating mutations of
the G-CSFR exhibit a hyperproliferative response to
G-CSF [27,28] Mutations in tyrosine kinase genes,
such as FLT3, JAK2, and KIT, frequently detected
in patients with de novo AML, have not been
described in patients with SCN transforming to
AML [29]. Instead, mutations of the CSF3R gene are
detected in up to 78% of patients with SCN develop-
ing AML [30]. Because the G-CSFR and tyrosine
kinases share many signaling pathways, these data sug-
gest that the mutant G-CSFR may provide a signal
necessary for malignant transformation. The observa-
tion that the dose intensity of G-CSF administered to
patients with SCN correlates with the risk of MDS/
AML has led some to conclude that G-CSF adminis-
tration may increase the risk of AML in congenital
neutropenia [31,32]. The finding that SCN patients
who are less responsive to even high doses of G-CSF
($8 mg/kg/day) are at a more than 3-fold increased
risk of transformation to AML/MDS compared with
those responsive to lower doses [33], however, would
indicate an intrinsic predisposition to MDS/AML
among this group. Furthermore, none of 383 patients
with cyclic neutropenia or idiopathic neutropenia
monitored by the Severe Chronic Neutropenia Inter-
national Registry, many of whom received daily or
alternate day G-CSF, developed leukemia [32,34,35].AML
Myeloid leukemia cells express G-CSF and
granulocyte-macrophage colony stimulating factor
(GM-CSF) receptors to varying degrees on their cell
surface. Exposure to myeloid growth factors increases
the proportion of leukemia cells in S phase [36-38] and
the incorporation of cytarabine into leukemia cell
DNA, improving cytotoxicity [36,38]. Despite
improved leukemia-free survival in some studies of
growth factor priming in AML, randomized trials
have not shown a significant survival benefit [39-44].
The lack of significant clinical benefit may result
from the modest increase in the proportion of blasts
recruited into S phase (6.0%-10.7% in one study [38]).
Myeloid growth factors can also result in leukemia
cell expansion [38], raising the possibility that growth
factor administration might adversely affect remission
and relapse rates. In general, the concern of an adverse
effect of myeloid growth factors on AML has not been
borne out by clinical trials; however, a recent study has
renewed this concern. The prospective multicenter
Acute Myeloid Leukemia Berlin-Frankfurt-Muenster
(AML-BFM) 98 study, testing the ability of G-CSF
to reduce infectious complications and improve out-
comes in children and adolescents with AML, reported
a trend toward an increased incidence of relapse in
standard-risk patients after G-CSF treatment [45].
Patients in the AML-BFM98 study overexpressing
the G-CSFR isoform IV (previously described in
AML [18]), who were randomly assigned to receive
G-CSF after induction, showed a 5-year cumulative
incidence of relapse of 50% compared with 14% in
those with low-level isoform IV expression (P 5 .04).
The level of isoform IV expression had no significant
effect on relapse in patients who did not receive
G-CSF. These data require substantiation. Evidence
that G-CSF administration can selectively sustain leu-
kemia cell populations overexpressing the G-CSFR
isoform IV could influence its use in AML, but would
not appear to be directly relevant to its potential to
transform normal hematopoietic cells.Acute Lymphoblastic Leukemia
G-CSF is used routinely in patients with acute
lymphoblastic leukemia (ALL). Among 412 children
treated on 2 consecutive ALL protocols from 1991
to 1998, all of whom received etoposide, 20 developed
MDS/AML at a median of 2.3 years [46]. Those who
received G-CSF experienced a significantly higher
incidence than those who did not. The 6-year cumula-
tive incidence of treatment-related AML ranged from
2.7% for children receiving neither radiation nor
G-CSF to 12.3% for children receiving both [46].
The association of the combination of etoposide and
G-CSF with the later development of AML is further
supported by a report of MDS/AML, all with 11q23
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underwent peripheral stem cell mobilization with this
combination [47]. Antiapoptotic effects of G-CSF and
other hematopoietic growth factors have been demon-
strated [48,49]. It seems likely that G-CSF can rescue
myeloid stem or progenitor cells from otherwise lethal
mutations that occur following chemotherapy [49].
Solid Tumors/Lymphoma
A review of 25 randomized trials of patients receiv-
ing chemotherapy for solid tumors or lymphoma dem-
onstrated a doubling of the incidence of MDS/AML in
those who received G-CSF [50]. The increased risk of
MDS/AML in these patients could be attributable to
the increased dose intensity of leukemogenic agents
administered to those receiving G-CSF, or to a direct
effect of the growth factor. Available data are insuffi-
cient to be certain. Patients with breast cancer treated
adjuvantly with cyclophosphamide and doxorubicin
are at an increased risk of MDS/AML if they receive
G-CSF [51]. The risk in these patients is double the
rate of those who do not receive G-CSF, raising the
possibility of a direct role for G-CSF [52]. Unfortu-
nately, the indication, cumulative dose, and duration
of G-CSF, as well as the doses of chemotherapy were
not available in this study, limiting any attempt to
establish whether the increased risk resulted from
G-CSF or the requirement for its use. If a causal rela-
tionship existed, the capacity of G-CSF to rescue
myeloid stem/progenitor cells from otherwise lethal
mutations would again appear to provide the most
likely mechanism.
Severe Aplastic Anemia
A significantly increased incidence of MDS/AML
was reported by the European Group for Blood and
Marrow Transplantation in Severe Aplastic Anemia
(SAA) patients receiving immunosuppressive therapy
and G-CSF compared with those not receiving
G-CSF [53]. Among 840 patients, the incidence of
MDS/AML in those receiving G-CSF was 10.9%
compared with 5.8% in those who did not. A Japanese
study demonstrated a substantial risk in children with
aplastic anemia receiving G-CSF, particularly those
resistant to immunosuppressive therapy [54]. Interest-
ingly, this group of children had a high incidence of
7q- and monosomy 7 identified by fluorescence in
situ hybridization (FISH), which would have been
missed with cytogenetics by conventional metaphase
analysis. It has been shown that CD341 cells in
MDS with monosomy 7 express an increased propor-
tion of the G-CSFR isoform IV mRNA and that
high concentrations of G-CSF increase the proportion
of monosomy 7 cells in vitro [55]. Together, these data
strongly suggest that pharmacologic doses of G-CSF
increase the proportion of preexisting monosomy 7cells rather than promoting the malignant transforma-
tion of normal hematopoietic cells.USEOFG-CSF INHEALTHYHEMATOPOIETIC
STEM CELL DONORS
In patients with life-threatening disorders, the po-
tential risk of the development of MDS/AML gener-
ally appears to be far outweighed by the therapeutic
benefit of G-CSF. The situation for healthy hemato-
poietic stem cell donors, however, is vastly different.
G-CSF has been increasingly used for the mobili-
zation and collection of hematopoietic stem cells.
Several mechanisms for the hematopoietic stem cell
mobilizing properties of G-CSF have been postulated,
including suppression of synthesis of CXCL12, a che-
mochine critical to stem cell homing [56], and induc-
tion of proteases that cleave adhesion molecules in
the bonemarrowmicroenvironment [57]. Hematopoi-
etic stem cells that are tethered to the bone marrow
stromal cells are released into the blood by these and
perhaps additional mechanisms.
Early studies using G-CSF mobilized peripheral
blood stem cells in place of marrow for allogeneic
transplantation in patients with advanced hematologic
malignancies suggested more rapid engraftment, less
transplant-related morbidity, and better outcomes
[58-61]. The use of peripheral blood progenitors for
allotransplantation expanded rapidly and now
exceeds the use of marrow by more than 2-fold [62].
Peripheral blood cells are used in 80% of allogeneic
transplantations recorded by the European Blood
and Marrow Transplant Registry [61]. Further, some
centers administer G-CSF before donation of marrow
to increase CD341 cell yield. A recent randomized
comparison [63], as well as registry data [64], indicate
statistically similar outcomes among large heteroge-
neous groups of patients transplanted with mobilized
blood or marrow. Compared with marrow, however,
following peripheral blood transplantation a higher
portion of patients develop chronic graft-versus-host
disease (cGVHD) and more continue to require
immunosuppressive treatment 5 years after transplan-
tation [63]. Statistical models favor the use of 1 source
or the other according to distinct patient characteris-
tics [65], but the results of ongoing studies are required
to validate specific recommendations.
In the absence of a clear benefit for the recipient,
and because there is no direct health benefit for a family
member or unrelated volunteer donating hematopoi-
etic cells, it is essential to minimize donor risk. The
avoidance of anesthesia, blood transfusion, and pro-
longed pain in the donor are potential benefits of
peripheral blood stem cell donation, but analyses com-
paring marrow with peripheral blood donation have
not generally demonstrated consequential differences
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defined benefit for the use of peripheral blood stem
cells for the vast majority of donors or recipients of
allotransplantations. Any potential increased risk for
the development of MDS/AML following the use of
G-CSF would be a critical consideration.
Anecdotal reports describe the development of
AML after G-CSF in peripheral blood hematopoietic
stem cell donors [69,73,74] and in a patient whose
autologous mobilized cells were used in a clinical
trial of myocardial regeneration [75], but studies of
large numbers of G-CSF mobilized stem cell donors
have failed to detect any increase in the incidence of
AML [76-78]. Holig and colleagues [68] monitored
the health of 3928 unrelated volunteer donors from
a single center for up to 5 years. With 8234 donor-
years follow-up, the incidence ofmyeloidmalignancies
was not significantly different from that expected in
the general population [68]. The National Marrow
Donor Program reported 9785 years of follow-up for
4015 donors and found no cases of leukemia [79].
One of the largest studies, from the German Marrow
Donor Registry, surveyed 8730 PBSC donors for a to-
tal of 30,777 observation years and detected only a sin-
gle case of AML in a donor of PBSC who happened
also to be a marrow donor [70]. We conducted a sys-
tematic Medline search and identified a total of 8 lon-
gitudinal studies on the incidence of AML among
healthy donors who were mobilized with G-CSF
(Table 1). In aggregate, 40,717 donors provided
151,016 donor-years of follow-up with 3 cases of
AML identified. This would correspond to an inci-
dence rate (IR) of 2 per 100,000 donor-years and to
an incidence rate ratio (IRR) of 0.6 (95% confidence
interval [CI], 0.1-1.9) based upon the overall reported
IR of 3.5 per 100,000 person-years in theUnited States
(SEER data, 2004-2008). The fact that the overall es-
timated risk of AML among surveyed PBSC donors
mobilized with G-CSF is lower than what would be
normally observed in the general population could
reflect underreporting of AML cases in existing obser-
vational studies. In any case, based on the 95% upper
CI of 1.9 for the IRR, even a 3-fold increase in theTable 1. Incidence of AML among Healthy PBSC Donors Mobilize
Author, Year Study Design Country N, Dono
Cavallaro, 2000 [77] Retrospective US/Italy 95
Anderlini, 2002 [80] Retrospective US 281
Tassi, 2005 [81] Prospective Italy 94
Confer, 2007 [82] Prospective US 4015
de la Rubia, 2008 [83] Prospective Spain 320
Holig, 2009 [68] Prospective Germany 3928
Halter, 2009 [84] Retrospective EU 23,254
Schmidt, 2010 [70] Retrospective Germany 8,730
NA indicates information not available from publications; EU, European Union
lating factor; PBSC, peripheral blood stem cell.
*Median years with the follow-up range in parentheses.
†As reported in the study or estimated based on median follow-up.incidence rate of AML amongPBSCdonors, compared
with population controls, would be statistically dis-
proved based on available data. The certainty of these
conclusions, however, is limited by the likelihood that
donors who develop leukemia might be lost to
follow-up or fail to complete surveys. The lack of
survey responses or other follow-up by a substantial
proportion of donors beyond 5 years of exposure to
G-CSF remains an important limitation of all the pre-
vious studies. In addition, with the exception of AML
following topoisomerase inhibitors, secondary leuke-
mia is rarely seen before 3 years and its risk duration
may exceed 10 years. Duration of follow-up is therefore
more important than patient-years and the aforemen-
tioned studies generally include only small numbers
of patients followed long term, further limiting the rel-
evance of the available data to the question of whether
G-CSF exposure might increase the risk of leukemia.
Because of the long latent period of secondary
AML and the extremely low incidence of AML in the
general population, at least 10 years of follow-up of
more than 2000 PBSC donors would be needed to
detect even a 10-fold increase in AML [85]. Thus,
although the absence of a demonstrable significant
increase in the risk of developing AML among PBSC
donors based on existing data remains somewhat reas-
suring, an adequately designed and powered study has
yet to be performed. Complicating such analyses is the
need to consider that HLA-identical sibling donors for
patients with leukemia may be predisposed to develop
leukemia [86] and that donors may undergo mobiliza-
tion more than once. Although second donations of
mobilized stem cells have not been associated with
an increased risk of donor complications [87], a broad
diversity of practices exists among individual donor
registries and minimal data exists regarding the
outcome of multiple donations.
In addition to the clinical data, basic work and the-
ory should be considered in trying to determine
whether G-CSF exposes donors to a risk of secondary
leukemia. Analysis of gene expression profiles demon-
strate changes in the expression of hundreds of genes
in healthy donors receiving G-CSF, but all return tod with G-CSF
rs Follow-up* Donor-Years of Follow-up† AML
3.6 (2.9-6.2) 342 0
3.3 (0.6-6.7) 927 0
2.5 (0.3-7) 235 0
NA (1-9) 9785 0
3 (1-5) 841 0
NA (0.1-5) 8234 1
Up to 12 99,875 1
3.3 (NA) 30,777 1
; AML, acute myelogenous leukemia; G-CSF, granulocyte colony-stimu-
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allelic replication timing and chromosomal abnormal-
ities have been described after G-CSF [89,90] but
appear limited to more mature CD34 negative cells
and have not been shown to affect CD34 positive
cells [91]. Down-regulation of NK cell activity both
in vitro [92] and in vivo [93] has been demonstrated
with the use of G-CSF. Although this impairment ap-
pears to be temporary, the exact timing of recovery of
NK function remains uncertain. These basic studies
indicate that genetic, epigenetic, and immune alter-
ations occur following G-CSF, but do not provide
a clear mechanism of transformation of normal
hematopoietic cells, and their clinical significance is
unclear [94].
Similarly, the available clinical data do not provide
evidence that G-CSF can transform normal hemato-
poietic stem cells in the absence of predisposing fac-
tors. In patients with AML with altered proportions
of G-CSF isoforms, G-CSF may promote the survival
of leukemic cells. In SCN and SAA, G-CSF mutations
or alterations in the proportions of specific isoforms in
some patients appear to render them susceptible to
leukemic transformation in the presence of sustained
pharmacologic levels of G-CSF. Following chemo-
therapy, G-CSF may promote the development of
myeloid malignancy by permitting greater dose inten-
sity of leukemogenic agents and by rescuing geneti-
cally damaged myeloid stem and/or progenitor cells.
None of these mechanisms appear directly relevant
to a healthy donor receiving low cumulative doses of
G-CSF. Nevertheless, the possibility that G-CSF
could increase the risk of development of leukemia in
stem cell donors exists and the available clinical data
do not exclude this possibility.
The World Marrow Donor Association (WMDA)
first published recommendations and requirements for
standardized practices to ensure the safety of unrelated
donors in 1994 and has subsequently updated them.
The 2010 guidelines state: ‘‘Donors may elect to
donate stem cells either by bone marrow harvest or
G-CSF mobilized PBSC collection’’ after they are
‘‘fully informed about the pros and cons of each
method’’ [95]. This is a reasonable standard for unre-
lated and related donors. In cases where the transplant
center will only accept a certain product, it may need to
search for a different donor. Although normal adult
donors can fully consent to the risks associated with
G-CSF administration, the situation is even more
complex for pediatric sibling donors who cannot give
true informed consent [96].
Until more conclusive data are obtained, trans-
plant physicians must explain the potential risk of
MDS/AML to all donors, related and unrelated, and
where appropriate, offer the option of marrow dona-
tion. Centers that presently rely exclusively, or nearly
so, on mobilized stem cells should be especially carefulthat every donor is fully informed of this potential risk
and provided with alternatives. Donor autonomy, in
addition to donor safety, should be paramount.ACKNOWLEDGMENTS
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